{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:13:13Z","timestamp":1785773593847,"version":"3.56.0"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>RET gene plays significant roles in the nervous system and many other tissues. Rearranged during transfection (RET) mutation is related to cell proliferation, invasion, and migration. Many invasive tumors (e.g., non-small cell lung cancer, thyroid cancer, and breast cancer) were found to have changes in RET. Recently, great efforts have been made against RET. Selpercatinib and pralsetinib, with encouraging efficacy, intracranial activity, and tolerability, were approved by the Food and Drug Administration (FDA) in 2020. The development of acquired resistance is inevitable, and a deeper exploration should be conducted. This article systematically reviewed RET gene and its biology as well as the oncogenic role in multiple cancers. Moreover, we also summarized recent advances in the treatment of RET and the mechanism of drug resistance.<\/jats:p>","DOI":"10.3389\/fonc.2023.1090757","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T17:50:50Z","timestamp":1676397050000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["A comprehensive overview of the relationship between RET gene and tumor occurrence"],"prefix":"10.3389","volume":"13","author":[{"given":"Lu","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanming","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.932353","article-title":"RET signaling pathway and RET inhibitors in human cancer","volume":"12","author":"Regua","year":"2022","journal-title":"Front Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v13.i4.276","article-title":"New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2","volume":"13","author":"Olmedo","year":"2022","journal-title":"World J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.10.156","article-title":"Potential unreliability of uncommon ALK, ROS1, and RET genomic breakpoints in predicting the efficacy of targeted therapy in NSCLC","volume":"16","author":"Li","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02551","article-title":"State-of-the-Art strategies for targeting RET-dependent cancers","volume":"38","author":"Subbiah","year":"2020","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.31662\/jmaj.2020-0021","article-title":"Roles of the RET proto-oncogene in cancer and development","volume":"3","author":"Takahashi","year":"2020","journal-title":"Jma J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.03.002","article-title":"Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer","volume":"155","author":"Yoh","year":"2021","journal-title":"Lung Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.12.114","article-title":"Identification of a novel KIF5B-RET, ABHD17C-RET double-fusion variant in lung adenocarcinoma and response to cabozantinib","volume":"15","author":"Zheng","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/09553002.2020.1730012","article-title":"Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage","volume":"97","author":"Mehta","year":"2021","journal-title":"Int J Radiat Biol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01642","article-title":"Receptor tyrosine kinases in osteosarcoma treatment: Which is the key target","volume":"10","author":"Tian","year":"2020","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.09.011","article-title":"A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma","volume":"138","author":"Hida","year":"2019","journal-title":"Lung Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2021.07.003","article-title":"Precision therapy for RET-altered cancers with RET inhibitors","volume":"7","author":"Thein","year":"2021","journal-title":"Trends Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01931-y","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1200\/JCO.22.00393","article-title":"Selpercatinib in patients with RET fusion-positive non-Small-Cell lung cancer: Updated safety and efficacy from the registrational LIBRETTO-001 phase I\/II trial","volume":"41","author":"Drilon","year":"2023","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/s41467-022-28848-x","article-title":"The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers","volume":"13","author":"Rosen","year":"2022","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-022-01259-x","article-title":"The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046","volume":"40","author":"Repetto","year":"2022","journal-title":"Invest New Drugs"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1016\/j.jtho.2020.12.018","article-title":"A novel oncogenic RET fusion variant in NSCLC: RELCH-RET","volume":"16","author":"Myrand","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0967","article-title":"FDA Approval summary: Pralsetinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions","volume":"27","author":"Kim","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12885-020-07714-3","article-title":"Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States","volume":"21","author":"Hess","year":"2021","journal-title":"BMC Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.992636","article-title":"Precision oncology for RET-related tumors","volume":"12","author":"Verrienti","year":"2022","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2183\/pjab.98.008","article-title":"RET receptor signaling: Function in development, metabolic disease, and cancer","volume":"98","author":"Takahashi","year":"2022","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-020-03268-9","article-title":"GDNF\/RET signaling in dopamine neurons in vivo","volume":"382","author":"Conway","year":"2020","journal-title":"Cell Tissue Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.10.599","article-title":"Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations","volume":"32","author":"Subbiah","year":"2021","journal-title":"Ann Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1124\/molpharm.120.000207","article-title":"Novel human-derived RET fusion NSCLC cell lines have heterogeneous responses to RET inhibitors and differential regulation of downstream signaling","volume":"99","author":"Schubert","year":"2021","journal-title":"Mol Pharmacol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13045-021-01063-9","article-title":"Therapeutic strategies in RET gene rearranged non-small cell lung cancer","volume":"14","author":"Drusbosky","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"100041","DOI":"10.1016\/j.esmoop.2020.100041","article-title":"Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA","volume":"6","author":"Della Corte","year":"2021","journal-title":"ESMO Open"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.01.006","article-title":"RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies","volume":"15","author":"Solomon","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3390\/genes11040424","article-title":"RET gene fusions in malignancies of the thyroid and other tissues","volume":"11","author":"Santoro","year":"2020","journal-title":"Genes (Basel)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"17588359221119318","DOI":"10.1177\/17588359221119318","article-title":"Efficacy and safety of selpercatinib in Chinese patients with advanced RET-altered thyroid cancers: results from the phase II LIBRETTO-321 study","volume":"14","author":"Zheng","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21731","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B30","doi-asserted-by":"publisher","first-page":"8661","DOI":"10.3390\/ijms22168661","article-title":"Current and future development in lung cancer diagnosis","volume":"22","author":"Nooreldeen","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.23022","article-title":"Fusion-positive non-small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implications","volume":"61","author":"Kazdal","year":"2022","journal-title":"Genes Chromosomes Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S186361","article-title":"KIF5B-RET fusion gene and its correlation with clinicopathological and prognostic features in lung cancer: a meta-analysis","volume":"12","author":"Cong","year":"2019","journal-title":"Onco Targets Ther"},{"key":"B33","doi-asserted-by":"publisher","first-page":"101911","DOI":"10.1016\/j.ctrv.2019.101911","article-title":"RET fusions in solid tumors","volume":"81","author":"Li","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.00216","article-title":"Discovery stories of RET fusions in lung cancer: A mini-review","volume":"10","author":"Takeuchi","year":"2019","journal-title":"Front Physiol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41574-021-00470-9","article-title":"The importance of the RET gene in thyroid cancer and therapeutic implications","volume":"17","author":"Salvatore","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15181","article-title":"Identification of RET fusions in a Chinese multicancer retrospective analysis by next-generation sequencing","volume":"113","author":"Shi","year":"2022","journal-title":"Cancer Sci"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e002891","DOI":"10.1136\/jitc-2021-002891","article-title":"Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer","volume":"9","author":"Negrao","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"893","DOI":"10.2217\/imt-2021-0035","article-title":"Efficacy of immune checkpoint inhibitor therapy in patients with RET fusion-positive non-small-cell lung cancer","volume":"13","author":"Bhandari","year":"2021","journal-title":"Immunotherapy"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00035-3","article-title":"The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020","volume":"10","author":"Pizzato","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-042220-015032","article-title":"Contemporary management of thyroid nodules","volume":"73","author":"Kobaly","year":"2022","journal-title":"Annu Rev Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41421-022-00479-y","article-title":"Integrated proteogenomic characterization of medullary thyroid carcinoma","volume":"8","author":"Shi","year":"2022","journal-title":"Cell Discov"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.11.013","article-title":"Molecular targets of tyrosine kinase inhibitors in thyroid cancer","volume":"79","author":"Fallahi","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.11.6129","article-title":"High prevalence of RET\/PTC rearrangements in Ukrainian and belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET\/PTC3 and the solid-follicular variant","volume":"84","author":"Thomas","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2021.57.10.3313852","article-title":"Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions","volume":"57","author":"Zheng","year":"2021","journal-title":"Drugs Today (Barc)"},{"key":"B45","first-page":"298","article-title":"Thyroid nodules: Advances in evaluation and management","volume":"102","author":"Kant","year":"2020","journal-title":"Am Fam Physician"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/ng0194-70","article-title":"Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC","volume":"6","author":"Mulligan","year":"1994","journal-title":"Nat Genet"},{"key":"B48","doi-asserted-by":"publisher","first-page":"4631","DOI":"10.3390\/ijms23094631","article-title":"Recent advances in thyroid cancer research","volume":"23","author":"Grimm","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000845","article-title":"A pilot study of preoperative vandetanib on markers of proliferation and apoptosis in breast cancer","volume":"44","author":"Spanheimer","year":"2021","journal-title":"Am J Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2019.66","article-title":"RET in breast cancer: pathogenic implications and mechanisms of drug resistance","volume":"2","author":"Lo Nigro","year":"2019","journal-title":"Cancer Drug Resist"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11826","article-title":"Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts","volume":"7","author":"Andreucci","year":"2016","journal-title":"Oncotarget"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkac778","article-title":"Super-enhancer-controlled positive feedback loop BRD4\/ER\u03b1-RET-ER\u03b1 promotes ER\u03b1-positive breast cancer","volume":"50","author":"Zheng","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.1038\/s41467-018-07341-4","article-title":"RET rearrangements are actionable alterations in breast cancer","volume":"9","author":"Paratala","year":"2018","journal-title":"Nat Commun"},{"key":"B54","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10911-020-09445-4","article-title":"Ret receptor has distinct alterations and functions in breast cancer","volume":"25","author":"Gattelli","year":"2020","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"B55","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s42003-022-03079-4","article-title":"Ret kinase-mediated mechanical induction of colon stem cells by tumor growth pressure stimulates cancer progression in vivo","volume":"5","author":"Nguyen Ho-Bouldoires","year":"2022","journal-title":"Commun Biol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01448-z","article-title":"RET isoforms contribute differentially to invasive processes in pancreatic ductal adenocarcinoma","volume":"39","author":"Lian","year":"2020","journal-title":"Oncogene"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-022-01138-z","article-title":"Identification of fusions with potential clinical significance in melanoma","volume":"35","author":"Moran","year":"2022","journal-title":"Mod Pathol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0206","article-title":"Real-world efficacy and safety of cabozantinib and vandetanib in advanced medullary thyroid cancer","volume":"31","author":"Koehler","year":"2021","journal-title":"Thyroid"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03093","article-title":"Open-label, single-arm, multicenter, phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer","volume":"39","author":"Wirth","year":"2021","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.640957","article-title":"Cabozantinib reverses topotecan resistance in human non-small cell lung cancer NCI-H460\/TPT10 cell line and tumor xenograft model","volume":"9","author":"Lei","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211019675","article-title":"Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program","volume":"13","author":"Illini","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.08.002","article-title":"Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial","volume":"33","author":"Griesinger","year":"2022","journal-title":"Ann Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.12.129","article-title":"Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced NSCLC with BRAF, HER2, or MET mutations or RET translocation: GFPC 01-2018","volume":"15","author":"Guisier","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.07.044","article-title":"Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)","volume":"124","author":"Dudnik","year":"2018","journal-title":"Lung Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non-Small-Cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03570","article-title":"Therapy for stage IV non-Small-Cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update","volume":"39","author":"Hanna","year":"2021","journal-title":"J Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw163","article-title":"Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers","volume":"27","author":"Drilon","year":"2016","journal-title":"Ann Oncol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"102153","DOI":"10.1016\/j.ctrv.2021.102153","article-title":"Diagnostics, therapeutics and RET inhibitor resistance for RET fusion-positive non-small cell lung cancers and future perspectives","volume":"96","author":"Lu","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.10.002","article-title":"Defining resistance mechanisms to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer","volume":"31","author":"Tan","year":"2020","journal-title":"Ann Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1022","article-title":"Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion","volume":"8","author":"Piotrowska","year":"2018","journal-title":"Cancer Discov"},{"key":"B72","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/1078-0432.CCR-20-2278","article-title":"Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib","volume":"27","author":"Rosen","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3390\/cancers13051091","article-title":"Chasing the target: New phenomena of resistance to novel selective RET inhibitors in lung cancer. updated evidence and future perspectives","volume":"13","author":"Fancelli","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.06.023","article-title":"Sensitivity and resistance of MET exon 14 mutations in lung cancer to eight MET tyrosine kinase inhibitors in vitro","volume":"14","author":"Fujino","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e12815","DOI":"10.1111\/jne.12815","article-title":"A monoclonal antibody raised against a synthetic oxytocin peptide stains mouse hypothalamic neurones","volume":"32","author":"Kogami","year":"2020","journal-title":"J Neuroendocrinol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2015.12.011","article-title":"Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer","volume":"93","author":"Horiike","year":"2016","journal-title":"Lung Cancer"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.09.127","article-title":"Intracranial activity of cabozantinib in MET exon 14-positive NSCLC with brain metastases","volume":"12","author":"Klempner","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.07.004","article-title":"Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET-rearranged lung cancers","volume":"13","author":"Drilon","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.canlet.2013.07.007","article-title":"Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models","volume":"340","author":"Okamoto","year":"2013","journal-title":"Cancer Lett"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.2174\/1568026621666210701143445","article-title":"Relevance of aromatase inhibitors in breast cancer treatment","volume":"21","author":"Sood","year":"2021","journal-title":"Curr Top Med Chem"},{"key":"B81","doi-asserted-by":"publisher","first-page":"PO.18.00386","DOI":"10.1200\/PO.18.00386","article-title":"Immunophenotype and response to immunotherapy of RET-rearranged lung cancers","volume":"3","author":"Offin","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000799","article-title":"Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies","volume":"5","author":"Hegde","year":"2020","journal-title":"ESMO Open"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3558","article-title":"FDA Approval summary: Selpercatinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions","volume":"27","author":"Bradford","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2021.06.005","article-title":"Central nervous system response to selpercartinib in patient with RET-rearranged non-small cell lung cancer after developing leptomeningeal disease on pralsetinib","volume":"23","author":"Tsui","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.010","article-title":"Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer","volume":"32","author":"Subbiah","year":"2021","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1090757\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T17:50:55Z","timestamp":1676397055000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1090757\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,14]]},"references-count":85,"alternative-id":["10.3389\/fonc.2023.1090757"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1090757","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,14]]},"article-number":"1090757"}}